BlinkLab is trading 11.04% up now at A$0.91, with no clear company-specific catalyst identified for August 20, 2026.
- The move appears unexplained by available news rather than directly attributable to the earlier study.
- The latest material update remains the August 5 European ADHD study, reporting 82% sensitivity and 83% specificity.
- Broader healthcare-sector context is inconclusive because the supplied sector indicator was negative.